Is skyrizi for plaque psoriasis?

Is Skyrizi approved for plaque psoriasis?

Skyrizi (risankizumab-rzaa) received FDA approval in 2019 for moderate to severe plaque psoriasis in adults. It is an IL-23 inhibitor that blocks the inflammatory pathway driving plaque formation.

How effective is Skyrizi for plaque psoriasis?

Clinical trials showed PASI 90 rates of 72-75% at week 16, with many patients maintaining clear or almost clear skin through week 52. Response rates were higher than those seen with adalimumab or ustekinumab in head-to-head studies.

How does Skyrizi compare to other psoriasis treatments?

Skyrizi offers dosing every 12 weeks after two starter doses, fewer injections than most IL-17 or TNF inhibitors, and strong durability of response. It does not require lab monitoring for tuberculosis or hepatitis B reactivation in the same way as some older biologics.

What side effects are patients asking about?

Common reactions include upper respiratory infections, headache, and injection-site reactions. Serious infections occurred at low rates in trials. Patients often want to know the infection risk compared with IL-17 inhibitors, which carry a higher candidiasis signal.

When does Skyrizi patent protection end?

The main composition-of-matter patent expires in 2033 in the US, with additional formulation and method-of-use patents extending coverage into the late 2030s. Biosimilar entry is therefore unlikely before 2034.

Who makes Skyrizi?

AbbVie manufactures and markets Skyrizi. [1]

[1] https://www.drugpatentwatch.com/patent/Skyrizi/